Pulmatrix, Inc. (NASDAQ:PULM) Sees Large Growth in Short Interest

Pulmatrix, Inc. (NASDAQ:PULM) was the target of a significant growth in short interest in the month of April. As of April 30th, there was short interest totaling 40,413 shares, a growth of 106.2% from the April 15th total of 19,602 shares. Approximately 1.1% of the company’s shares are sold short. Based on an average daily volume of 43,030 shares, the short-interest ratio is currently 0.9 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulmatrix in a report on Friday, March 27th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Pulmatrix Stock Performance

Shares of NASDAQ PULM traded down $0.02 during midday trading on Friday, reaching $1.25. The stock had a trading volume of 17,492 shares, compared to its average volume of 31,072. The company’s 50 day moving average price is $1.56 and its 200 day moving average price is $2.73. Pulmatrix has a twelve month low of $1.16 and a twelve month high of $9.37. The firm has a market cap of $4.57 million, a price-to-earnings ratio of -1.02 and a beta of 1.94.

Pulmatrix (NASDAQ:PULM) last announced its quarterly earnings data on Friday, May 15th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Pulmatrix stock. DRW Securities LLC purchased a new position in Pulmatrix, Inc. (NASDAQ:PULM) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 20,505 shares of the biotechnology company’s stock, valued at approximately $46,000. 11.84% of the stock is currently owned by hedge funds and other institutional investors.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).